CVS CVS Health
Scale franchise at trough margins; value depends on whether Aetna's recovery returns margins to about 3.8%.
The story
CVS is a vertically integrated health giant (Aetna insurance, Caremark PBM, retail pharmacy, Oak Street/Signify care delivery) with enormous scale but thin, cyclical margins. Margins collapsed as Medicare Advantage medical costs spiked and retail pharmacy eroded, and a repricing-driven Aetna recovery is now underway. It is a mature business: growth roughly tracks healthcare spending, and value depends on getting margins back toward historical norms rather than on expansion.
Revenue growth of about 5% fades to 2.5%, in line with nominal healthcare spending. Operating margin recovers from a depressed 2.1% to 3.8% over four years as MA repricing and PBM and retail restructuring take hold. That is below the 4.5%+ of the pre-2023 peak, reflecting regulatory and PBM pressure. The baseline of $5 per share is an artifact of carrying trough margins forward; at a normalized margin, value reconciles with a market price that already embeds a partial recovery.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 7y |
| Target operating margin | 3.8% |
| Years to target margin | 4 |
| Sales-to-capital | 3.00 |
| Beta | 0.90 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.8% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 37.45B |
| PV of terminal value | 103.35B |
| Equity value | 82.83B |
| ÷ shares → per share | $64.76 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 435.84B | 5.0% | 2.6% | 9.01B | 6.92B | 2.09B | 1.93B |
| 2 | 455.82B | 4.6% | 3.0% | 10.95B | 6.66B | 4.30B | 3.63B |
| 3 | 474.81B | 4.2% | 3.4% | 13.00B | 6.33B | 6.67B | 5.18B |
| 4 | 492.61B | 3.8% | 3.8% | 15.14B | 5.94B | 9.21B | 6.57B |
| 5 | 509.03B | 3.3% | 3.8% | 15.65B | 5.47B | 10.18B | 6.68B |
| 6 | 523.88B | 2.9% | 3.8% | 16.10B | 4.95B | 11.16B | 6.73B |
| 7 | 536.98B | 2.5% | 3.8% | 16.51B | 4.37B | 12.14B | 6.73B |
Key risks
- Medicare Advantage utilization and star-ratings or rate pressure keep Aetna's MLR elevated
- PBM reform legislation and FTC actions compress Caremark spread and rebate economics
- Continued retail pharmacy decline, reimbursement cuts, and heavy leverage (~$56B net debt) limit flexibility
Catalysts
- Aetna margin recovery from MA repricing and benefit cuts showing up in quarterly MLR
- Deleveraging plus store closures and cost programs lifting free cash flow and EPS guidance